Oncolys BioPharma: “Stobo IR Conference 2024 in Sapporo Bio-Related Stocks Special” Archived Video Release Notice
Oncolys BioPharma: Notice of presentation on oncolytic virus at the 62nd Annual Meeting of the Japanese Society for Cancer Therapy
Oncolys BioPharma: Notice regarding mass exercise of the 20th Stock Acquisition Rights (with exercise price correction clauses and suspension of exercise clauses) issued by third party allotment
Oncolys BioPharma: Notice of co-hosting a luncheon seminar on virus therapy at the 62nd Annual Meeting of the Japanese Society for Cancer Therapy
Oncolys BioPharma: Announcement of the conference presentation of oncolytic virus OBP-301 at the 62nd Annual Meeting of the Japanese Society for Cancer Therapy
Oncolys BioPharma: Notice regarding mass exercise of the 20th Stock Acquisition Rights (with exercise price correction clauses and suspension of exercise clauses) issued by third party allotment
Oncolys BioPharma: Announcement of the final results report on the OBP-601 C9-ALS (amyotrophic lateral sclerosis) Phase2a test at the 2024 Annual NEALS Meeting
Oncolys BioPharma: Notice regarding mass exercise of the 20th Stock Acquisition Rights (with exercise price correction clauses and suspension of exercise clauses) issued by third party allotment
Oncolys BioPharma: Notice regarding the monthly exercise status of the 20th Stock Acquisition Rights (with exercise price correction clauses and suspension of exercise clauses) issued by third party allotment
Oncolys BioPharma: Notice regarding the status of system development for proper use of oncolytic virus OBP-301 after marketing
Oncolys BioPharma: Notice regarding responses to inquiries
Oncolys BioPharma: Announcement of the release of the analyst report
Oncolys BioPharma: Notice regarding the monthly exercise status of the 20th Stock Acquisition Rights (with exercise price correction clauses and suspension of exercise clauses) issued by third party allotment
Oncolys BioPharma: Announcements of individual stocks: Participation notice for the Stobo IR Conference 2024 Bio-related stock feature in Sapporo.
Oncolys BioPharma: Announcements of individual stocks: Notice of the publication of LogMee Finance's written report on the interim earnings conference for the period ending December 2024.
Oncolys BioPharma: Announcements of individual stocks regarding the mass exercise of the 20th subscription rights (including the exercise price adjustment clause and exercise suspension clause) issued through third-party allotment.
Oncolys BioPharma: Announcements of individual stocks regarding the recognition of non-operating income and expenses.
Oncolys BioPharma: Unconsolidated financial statements [Japan standard] for the six months ending on June 30, 2024.
Oncolys BioPharma: Announcements of individual stocks regarding responses to inquiries.
Oncolys BioPharma: Announcements of individual stocks: Complete registration of Phase I clinical trial of telomelysin and chemical radiation combination therapy.
No Data
No Data